Skip to main content
Psych Congress  

The Impact of Injection Centers on Adherence to Atypical Long-Acting Injectable Antipsychotics Among Patients with Schizophrenia Enrolled in a Novel Support Program

Authors  
Kruti Joshi, MPH
Carmela Benson, MS, MSHP
John Fastenau, RPh
Kate Lapane, PhD
Sponsor  
Janssen Scientific Affairs

Background: Among patients with schizophrenia, non-adherence to antipsychotic medication increases the likelihood of relapse and associated hospitalization. Atypical long-acting injectable antipsychotics (LAIs) may increase adherence, yet few studies have evaluated correlates of adherence to LAI treatment.  

Objective: To compare patient characteristics and adherence among Janssen® Connect® (JC) patients who requested the injection center offering to those who did not request the offering.

Methods: We used the 3.5 year JC administrative files from December 2010-April 2014 to evaluate adherence of patients whose health care provider determined paliperidone palmitate to be the most clinically appropriate treatment option. We calculated: 1) receipt of ≥ one LAI; and 2) proportion of days covered (PDC) among those with ≥ 60 days of follow-up. A logistic model identified factors associated with PDC≥80%.

Results:  This analysis included 9,354 enrollees prescribed paliperidone palmitate, of which 39.8% requested injection center offering. Of those requesting an injection center offering, 57.0% received ≥1 LAI relative to 37.5% among those not requesting an injection center offering (p-value<0.0001). Overall, 87.4% of 2,659 patients included in the PDC analysis achieved PDC≥80%.  Of which, patients requesting the injection center offering were more than four times as likely to achieve PDC≥80% than those who did not (adjusted Odds Ratio (aOR): 4.55; 95 % Confidence Interval (CI): 2.98 to 6.95).

Conclusions:  Access to injection centers for patients to receive LAIs may increase adherence to the prescribed LAIs.  A summative evaluation of this program support is on-going.

Back to Top